Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Igc Pharma Inc
(NY:
IGC
)
0.3530
+0.0078 (+2.26%)
Official Closing Price
Updated: 8:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
89,537
Open
0.3550
Bid (Size)
0.3411 (10)
Ask (Size)
0.3599 (2)
Prev. Close
0.3452
Today's Range
0.3410 - 0.3624
52wk Range
0.2501 - 0.9099
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease
September 04, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Product Safety
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
September 04, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Performance
YTD
+27.90%
+27.90%
1 Month
-9.72%
-9.72%
3 Month
-18.21%
-18.21%
6 Month
+6.17%
+6.17%
1 Year
-9.42%
-9.42%
More News
Read More
The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts
September 03, 2024
Via
Benzinga
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting
August 27, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Regulatory Compliance
Exposures
Artificial Intelligence
Intellectual Property
Legal
IGC Announces Results of its 2024 Annual Stockholders Meeting
August 26, 2024
From
IGC Pharma, Inc.
Via
Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease
August 22, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
August 22, 2024
From
IGC Pharma, Inc.
Via
Business Wire
InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) AI-Driven Approach Reveals ‘Promising Opportunity’ for IGC-1A to Be a Potential GLP-1 Agonist
August 20, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
August 20, 2024
From
IGC Pharma
Via
Business Wire
IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025
August 12, 2024
Via
InvestorPlace
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2025 Financial, Operational Results Report
August 09, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research
August 09, 2024
Via
Benzinga
IGC Pharma Reports First Quarter Fiscal 2025 Results
August 08, 2024
From
IGC Pharma, Inc.
Via
Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Buy’ Recommendation in AGP’s Analyst Coverage Research Report
July 18, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
July 18, 2024
From
IGC Pharma, Inc.
Via
Business Wire
BioMedNewsBreaks — IGC Pharma Inc.’s (NYSE American: IGC) TGR-63 Demonstrates Blood-Brain Barrier Permeability in Preliminary Findings
July 09, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
July 09, 2024
From
IGC Pharma, Inc.
Via
Business Wire
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Positive Data from TGR-63 Preclinical Studies
June 26, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Financial Report for Fiscal Year
June 25, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
June 25, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 25, 2024
Via
InvestorPlace
IGC Stock Earnings: IGC Pharma Meets EPS, Beats Revenue for Q4 2024
June 24, 2024
Via
InvestorPlace
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
June 24, 2024
From
IGC Pharma, Inc.
Via
Business Wire
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Execs Slated to Present at Upcoming Ascendiant Capital Markets Event
June 18, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
June 18, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.